Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
comments(0)
5-min edit window · permanent after that